The European Union is providing nearly €15 million ($18.1 million) over five years to improve personalized medicine options for people with drug-resistant high-grade serous ovarian cancer. The DECIDER project, funded by the EU’s Horizon 2020 research and innovation program, will apply artificial intelligence methods to develop new diagnostic tools to identify — earlier and more accurately — those patients whose cancer is not responding to treatments. The goal is to find effective drug combinations for…
You must be logged in to read/download the full post.
The post €15M EU Project Seeks to Improve Personalized Medicine Options appeared first on BioNewsFeeds.